| Name: |
METHOTRIMEPRAZINE (NozinanR) |
| Classification: |
phenothiazine; neuroleptic
- antipsychotic
- anxiolytic
- sedative and analgesic properties
|
| Dose: |
- Bolus:
- Infusion:
- 2-8 mg/hr, titrated to patient response
|
| Administration: |
IV Infusion:
50 mg/50 ml D5W, NS for syringe pump infusion or 100mg/100ml D5W, NS |
| Adverse Effects: |
- anticholinergic effects:
- urinary retention
- tachycardia
- orthostatic hypotension
- drowsiness
- agranulocytosis (rare)
- altered thermic response (poikilithermic effect) thus may not be able to adapt to temperature changes
|
| Cautions: |
- in patients with glaucoma, due to anticholingergic effects
- in epileptic patients due to possible reduction of seizure threshold
|
| Drug Interactions: |
- methotrimprazine + epinephrine = diminished effect of epinephrine on blood pressure
- methotrimprazine + CNS depressants = increased CNS depressant effects
|
| Monitoring Therapy: |
- BP
- HR, ECG
- urine output
- appropriate response to ambient temperature, temperature
- white blood cell count
- level of sedation
|
| CCTC Protocol: |
- May be administered by IV infusion by an RN in CCTC.
|
Print
Handheld
Contrast
